CB2 Receptors on Immune Cells Can Directly Suppress the Autoimmune Attack in MS | Research

The takeaway

The CB2 cannabinoid receptor, primarily expressed on immune cells, can directly suppress the autoreactive T cells that cause nervous system damage in multiple sclerosis.

Read this if you have MS and want to understand how cannabinoids might affect the disease process itself, not just symptoms.

CB2 receptor (immune system) directly suppresses autoimmune attack on nerve cells

What the researchers found

This review focused on the CB2 cannabinoid receptor's role in controlling autoimmune inflammation in the central nervous system.

While THC activates both CB1 (mainly brain) and CB2 (mainly immune system) receptors, the generation of mice lacking specific cannabinoid receptors has allowed researchers to separate these functions. Studies using CB2-specific approaches showed that this receptor directly regulates T cell effector functions, particularly the autoreactive lymphocytes that attack myelin in MS.

Endogenous cannabinoids (endocannabinoids) also bind CB2 and exert immune-modulatory effects, suggesting the body has a built-in system for regulating autoimmune responses through cannabinoid signaling.

The review argued that CB2-targeted therapies could potentially suppress the autoimmune component of MS without causing the psychoactive effects mediated by CB1 receptors in the brain.

Why it matters

If CB2 receptors can suppress the autoimmune attack in MS without affecting brain CB1 receptors, it could lead to cannabinoid-based treatments that modify MS disease progression without causing intoxication or cognitive effects.

The numbers in context

CB2 is primarily expressed on immune cells. Studies used CB1 and CB2 knockout mice to discriminate receptor-specific functions. THC binds both CB1 and CB2. Endocannabinoids also activate CB2.

How the study worked

Narrative review of preclinical research on CB2 receptor function in autoimmune CNS inflammation, drawing primarily on knockout mouse studies and in vitro immune cell experiments.

What this study cannot tell us

Most evidence was from animal models. Translating mouse immune findings to human MS is uncertain. No CB2-selective drugs had been tested in MS clinical trials at the time of the review.

How to read the evidence

This is a narrative review of primarily animal and in vitro research, providing moderate mechanistic evidence for CB2's role in autoimmune CNS inflammation.

When this study was published

Published in 2008. CB2-selective compounds have since been developed and tested in various inflammatory conditions, though none are yet approved for MS.

The bigger picture

This review articulated the therapeutic promise of selective CB2 activation for autoimmune diseases. While earlier work (RTHC-00288) showed CB1 is needed for anti-spastic effects, this review showed CB2 could address the underlying autoimmune process, representing a complementary approach.

Questions still open

Can CB2-selective agonists slow human MS progression without psychoactive effects? Do MS patients have altered CB2 expression on their immune cells?

Common questions

What is the difference between CB1 and CB2?

CB1 receptors are mainly in the brain and mediate cannabis's psychoactive effects. CB2 receptors are mainly on immune cells and modulate inflammation. A drug targeting only CB2 could theoretically reduce autoimmune inflammation without causing a "high."

Could this lead to a cure for MS?

Not a cure, but potentially a disease-modifying therapy. Suppressing the autoimmune attack could slow MS progression. However, this was a review of early research, and clinical trials of CB2-targeted MS treatments are still needed.

Read the original research

Direct suppression of autoreactive lymphocytes in the central nervous system via the CB2 receptor.

British journal of pharmacology, 153(2), 271-6

View on PubMed ↗

Citation

Dittel, B N. (2008). Direct suppression of autoreactive lymphocytes in the central nervous system via the CB2 receptor.. British journal of pharmacology, 153(2), 271-6.